NKTR-358, a Modified IL-2 Pathway Agonist for Selective Expansion of Tregs in vivo

Time: 1:30 pm
day: Day One | Track B | Morning


  • Discussing the design of NKTR-358 using polymer chemistry
  • Exploring NKTR-358’s mechanism of action and preclinical development
  • Presenting Clinical highlights demonstrating Treg specificity and an optimal pharmacology profile for the treatment of autoimmune diseases